The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Circulating cytokines and angiogenic factors (CAF) as markers of clinical response in the study of trametinib (T) plus gemcitabine (G) versus placebo (P) plus gemcitabine for patients (pts) with untreated metastatic adenocarcinoma of the pancreas (MEK113487).
John Heymach
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Hai T. Tran
No relevant relationships to disclose
Andrew B. Nixon
Consultant or Advisory Role - GlaxoSmithKline
Herbert Hurwitz
Consultant or Advisory Role - Bayer; Regeneron; Roche/Genentech; Sanofi
Honoraria - Roche/Genentech
Research Funding - Lilly; Regeneron; Roche/Genentech; Sanofi
Jeffrey R. Infante
Consultant or Advisory Role - GlaxoSmithKline (U)
Robert C. Gagnon
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Klaudia Steplewski
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Ngocdiep T. Le
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Yuan Liu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline